OSR Health Board Authorizes Management to Engage with Potential Acquirer of OSRK for Reverse Takeover
The proposed exchange would leave OSRH controlling the acquirer, which would own all of OSRK, rather than directly holding its current stake.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
OSR Health (OSRH) authorized management to pursue a sale of its controlling OSRK interest to an undisclosed Nasdaq-listed acquirer through a potential reverse takeover.
OSRH owns approximately 84.5% of OSRK, its principal operating subsidiary. The proposed stock-for-stock exchange would make OSRH the acquirer's controlling shareholder, with the resulting company owning 100% of OSRK. The contemplated total value, including a proposed earn-out for OSRH, would exceed the valuation applied in the February 2025 deSPAC acquisition.
The company believes the exchange could turn its privately held OSRK stake into listed equity. A transaction requires definitive agreements, board and stockholder approval, and applicable regulatory approvals. Separately, OSRH is pursuing OTCQB quotation in the near term, subject to OTC Markets Group approval.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed stock-for-stock exchange would give OSRH control of the acquirer, which would own 100% of OSRK.
- Minor point. Forward-looking: it has not happened yet and may not happen.Contemplated total value, including a proposed earn-out, would exceed OSRK's February 2025 acquisition valuation.
- Minor point. Forward-looking: it has not happened yet and may not happen.Listed equity could replace OSRH's privately held OSRK stake, improving liquidity in the company's view.
- Minor point. Forward-looking: it has not happened yet and may not happen.OTCQB application is being pursued, with quotation targeted in the near term.
Negative
- Moderate pointPotential transaction still requires negotiation and execution of definitive agreements.
- Minor point. Forward-looking: it has not happened yet and may not happen.Board, stockholder and applicable regulatory approvals would be required for any transaction.
- Minor pointOTCQB quotation remains subject to OTC Markets Group approval.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BELLEVUE, WA / ACCESS Newswire / November 2, 2026 / OSR Health, Inc. (OTC PINK:OSRH) ("OSR Health" or the "Company") today announced that its Board of Directors has authorized management to pursue a sale of the Company's controlling interest in OSR Holdings Co., Ltd. ("OSRK") to an undisclosed Nasdaq-listed counterparty ("Acquirer") for a potential reverse takeover.
The Proposed Transaction
The total value of the contemplated transactions, including the proposed earn-out scheme for OSRH, would be greater than the valuation applied when the Company acquired OSRK through a deSPAC transaction in February 2025. OSRK, approximately
The Board's authorization is part of a plan to unlock the value of the Company's portfolio. Under the plan, the Company seeks to exchange its privately held equity interest in OSRK for shares of the Acquirer in a stock-for-stock transaction. As a result, OSR Health would become the controlling shareholder of Acquirer (or post-closing, "NewCo") that would own
Rationale for Shareholders
The Company believes that a transaction structured in this manner could deliver key benefits to OSR Health shareholders as it would provide a transparent market valuation for the Company's portfolio of businesses being marked-to-market with the NewCo on Nasdaq and transform the liquidity profile of the Company's main asset, its approximately
"Following the Nasdaq decision, we have moved quickly to put in place a clear path to realize the value of our portfolio for shareholders," said Peter Hwang, Chief Executive Officer of OSR Health. "The Board's authorization gives management a clear mandate to actively engage in opportunities, and accordingly we look forward to updating our shareholders as we make progress."
Path to a National Exchange and OTCQB Uplisting
A sale of OSRK is a key pillar of OSR Health's plan to return its portfolio of businesses to a national securities exchange. In parallel, the Company is pursuing an application to have its common stock quoted on the OTCQB, which it is targeting in the near term, subject to approval by OTC Markets Group.
Conditions
Any transaction would be subject to, among other things, the negotiation and execution of definitive agreements, approval by the Company's Board of Directors and stockholders, and applicable regulatory approvals. There can be no assurance that any transaction will be agreed or completed, or as to its terms or timing. The Company does not intend to comment further unless and until it determines that further disclosure is appropriate or required.
# # #
About OSR Health, Inc.
OSR Health, Inc. (OTC: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Health engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.osr-health.com.
Investor Contact
OSR Health, Inc. Investor Relations
ir@osr-health.com
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding a potential sale of the Company's interest in OSRK, its terms, consideration and timing, its anticipated benefits, and the Company's plans to seek quotation on the OTCQB. These statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including:
- the possibility that the Company will not enter into an agreement for, or complete, a sale on acceptable terms or at all;
- that any contingent or non-cash consideration may not be realized in whole or in part;
- the receipt of required approvals, including by the Company's stockholders;
- claims by the Company's creditors;
- the Company's ability to meet the eligibility requirements for, and obtain approval of, quotation on the OTCQB;
- the Company's liquidity and financial condition; and
- the other risks described in the Company's filings with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
The Company undertakes no obligation to update any forward-looking statement except as required by law.
SOURCE: OSR Health, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transaction is OSR Health proposing for OSRK?
OSR Health proposes exchanging its approximately 84.5% interest in OSRK for shares of an undisclosed Nasdaq-listed acquirer. OSRH would become the acquirer's controlling shareholder, and the resulting company would own 100% of OSRK. Management has authorization to pursue the potential transaction; definitive agreements remain to be negotiated and executed.
How does the proposed OSRK transaction valuation compare with OSR Health's acquisition valuation?
The contemplated transactions' total value, including a proposed earn-out for OSRH, would exceed the valuation applied when OSR Health acquired OSRK through a deSPAC transaction in February 2025.